Marinus Pharmaceuticals, Inc.
MRNS · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | -$0 | $0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 21.6% | 66% | 793.2% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 93.8% | 98.7% | 90.4% | -2,839.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -405% | -20% | -622.5% | -3,892.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -456.3% | -77.8% | -662.5% | -3,879% |
| EPS Diluted | -2.63 | -0.51 | -2.77 | -2.44 |
| % Growth | -415.7% | 81.6% | -13.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |